Lena Tagmose

This inventor holds 13 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignee: H. Lundbeck A/s. Active years: 2016-2024.

USPTO Granted Patents = 13 (Patent Applications = 5)

% Patents Active = 46.2

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 38(Granted Patents)

Location History:

Valby, DK (2018 - 2020)
Lyngby, DK (2016 - 2021)

Company Filing History:

13 out of 513

H. Lundbeck A/s

patents

Years Active: 2016-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129289 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2024-10-29),

2. 11111290 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2021-09-07),

3. 10647762 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2020-05-12),

4. 10603310 - 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors (2020-03-31),

5. 10487142 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2019-11-26),

6. 10472415 - Antibodies specific for hyperphosphorylated tau and methods of use (2019-11-12),

7. 10059669 - 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease (2018-08-28),

8. 10058540 - 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors (2018-08-28),

9. 10045974 - 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors (2018-08-14),

10. 10011596 - 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors (2018-07-03),

11. 10004738 - Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines (2018-06-26),

12. 9353084 - 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease (2016-05-31),

13. 9346797 - 2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors (2016-05-24),

Title: Lena Tagmose: Innovator in Alzheimer's Research

Introduction

Lena Tagmose is a prominent inventor based in Lyngby, Denmark. She has made significant contributions to the field of biomedical research, particularly in the development of therapies for Alzheimer's disease. With a total of 13 patents to her name, her work focuses on innovative solutions to combat neurodegenerative disorders.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Antibodies specific for hyperphosphorylated tau and methods of use thereof." This invention relates to a class of monoclonal antibodies that specifically bind to the phosphorylated serine 396 residue on pathological hyperphosphorylated tau (pS396) with improved affinity. The methods of using these antibodies and their tau-binding fragments aim to provide new treatment options for Alzheimer's disease and other tauopathies.

Career Highlights

Lena Tagmose has established herself as a key figure in her field through her innovative research and patent contributions. Her work at H. Lundbeck A/S has positioned her at the forefront of Alzheimer's research, where she continues to explore new therapeutic avenues.

Collaborations

Throughout her career, Lena has collaborated with notable colleagues, including Mauro Marigo and Karsten Juhl. These partnerships have enhanced her research efforts and contributed to the advancement of her innovative projects.

Conclusion

Lena Tagmose is a trailblazer in the field of Alzheimer's research, with a strong portfolio of patents that reflect her dedication to finding effective treatments for neurodegenerative diseases. Her contributions continue to inspire advancements in biomedical innovation.